Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
Nuwellis announced the publication of ULTRA-Peds Registry results in Pediatric Nephrology, providing multicenter clinical evidence for the Aquadex SmartFlow System in infants and children, including patients under 10 kg. The study covered 91 pediatric patients across seven children's hospitals, with 87% surviving their treatment course and 86.5% of procedures completed without interruption. Combined with earlier cohorts, real-world evidence now spans 208 pediatric patients.
Key figures
- Drug Name
- Aquadex SmartFlow System
- Phase Of Trial
- ULTRA-Peds Registry (multicenter observational)
- Hospitals
- 7
- Survival rate
- 87%
- Pct under 10kg
- 62%
- Patients enrolled
- 91
- Patients under 5kg
- 41
- Planned duration completion
- 68%
- Total pediatric patients all cohorts
- 208
- Procedures completed without interruption
- 86.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.